grant
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoVAfricaAlpha-FucosyltransferasesAmanAngolaAnimal ModelAnimal Models and Related StudiesAntibodiesAntibody TherapyAntigenic DeterminantsBindingBinding DeterminantsBinding SitesBioavailabilityBiological AgentBiological AvailabilityBiological ProductsBiological Response Modifier TherapyBiological TherapyBlood Chemical AnalysesBlood Chemical AnalysisBlood SerumCHO CellsCOVID-19 virusCOVID19 virusCase Fatality RatesCaviaCell BodyCell LineCellLineCellsCessation of lifeChinese Hamster OvaryChinese Hamster Ovary CellClinicalClinical Treatment MoabCoV-2CoV2CollaborationsCombining SiteComparative StudyComplete Blood CountCrab-Eating MacaqueCrab-Eating MonkeyCynomolgus MonkeyCynomolgus macaqueDNA mutationDataDeathDevelopmentDiseaseDisease OutbreaksDisease OutcomeDisorderDoseDrug KineticsEBOVEbolaEbola Hemorrhagic FeverEbola Virus DiseaseEbola diseaseEbola virusEbola-like VirusesEngineeringEpitopesExhibitsFDA approvedFatality rateFiloviridaeFilovirusFrankfurt-Marburg Syndrome VirusFucosyltransferaseFundingFutureGP1GP2GP2 geneGTP-Binding Protein 1GTPBP1GTPBP1 geneGenerationsGenetic ChangeGenetic defectGenetic mutationGlycoprotein 2, Zymogen Granule MembraneGlycoproteinsGuinea PigsGuinea Pigs MammalsHumanImmune mediated therapyImmunologically Directed TherapyImmunotherapyIndividualInfectionInjectionsInvestigatorsLeadM fascicularisM. fascicularisMAb TherapeuticsMacaca cynomolgusMacaca fascicularisMacaca irusMarburgMarburg Virus DiseaseMarburg hemorrhagic feverMarburg virusMarburg-like VirusesMarburgvirusMeasuresModern ManMolecular InteractionMonitorMonoclonal AntibodiesMutationNHP modelsOrthoebolavirusOrthomarburgvirusOutbreaksOutcomePK/PDPb elementPharmacodynamicsPharmacokineticsPhasePhysiologic AvailabilityPropertyReactive SiteRegression AnalysesRegression AnalysisRegression DiagnosticsReportingResearchResearch PersonnelResearchersRisk ReductionSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SBIRSampling StudiesSeriesSerumSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome related corona virus 2Small Business Innovation ResearchSmall Business Innovation Research GrantStatistical RegressionStrains Cell LinesSurfaceSurvival AnalysesSurvival AnalysisTestingTherapeuticTherapeutic Monoclonal AntibodiesTimeTransfectionVaccinesVariantVariationViralViral DiseasesViral Hemorrhagic FeversViremiaVirusVirus DiseasesWest AfricanWuhan coronavirusZEBOVZaire Ebola virusZaire ebolavirusZymogen Granule Membrane Glycoprotein 2animal efficacyanimal ruleantibody based therapiesantibody immunotherapyantibody treatmentantibody-based therapeuticsantibody-based treatmentbasebasesbiological therapeuticbiological treatmentbiologically based therapeuticsbiologicsbiopharmaceuticalbiotherapeutic agentbiotherapeuticsbiotherapyblood chemistrycell bankclinical developmentcoronavirus disease 2019 viruscoronavirus disease-19 viruscultured cell linedesigndesigningdetermine efficacydevelop a vaccinedevelop vaccinesdevelopment of a vaccinedevelopmentaldrug candidateeffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy studyevaluate efficacyexamine efficacyexperimentexperimental researchexperimental studyexperimentsgenome mutationguinea pig modelhCoV19heavy metal Pbheavy metal leadhemorrhagic feverimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapylong-tailed macaquemAbsmanufacturemodel of animalmonoclonal Absmonoclonal antibody drugsnCoV2neutralizing antibodyneutralizing mAbneutralizing monoclonal antibodiesnon-human primatenonhuman primatenonhuman primate modelsnovelpathogenpharmacokinetics and pharmacodynamicsprimary end pointprimary endpointproduct developmentprotective efficacyprototypereceptor bindingreceptor boundreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskrisk-reducingsecondary end pointsecondary endpointsobersobrietystable cell linesuccesstherapeutic agent developmenttherapeutic candidatetherapeutic developmenttherapeutic mAbstherapeutically effectivevaccine developmentviraemiaviral disease outbreakviral infectionviral outbreakviral sepsisvirus disease outbreakvirus infectionvirus-induced diseasevirusemia
Description preview
Project Summary
Ebola (EBOV) and Marburg (MARV) viruses cause hemorrhagic fever disease in humans and nonhuman
primates (NHPs) with case-fatality rates as high as 90%. The 2013-2016 Ebola Virus Disease (EVD) outbreak
led to over 28,000 cases and 11,000 deaths and took an enormous toll on the economy of West African nations,
in the absence of any…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click